Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase

Weiguo Zhao, Ronald Tilton, John A. Corbett, Michael L. McDaniel, Thomas P. Misko, Joseph R. Williamson, Anne H. Cross, William F. Hickey

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

This study assessed the role of de novo nitric oxide (NO) production in the pathogenesis of experimental allergic encephalomyelitis (EAE) by using aminoguanidine (AG), an inhibitor of nitric oxide synthase (NOS), which preferentially inhibits the cytokine- and endotoxin-inducible isoform of NOS versus the constitutive isoforms consisting of endothelial and neuronal NOS. The maximum clinical severity of EAE and the duration of illness were significantly reduced or totally inhibited by twice daily subcutaneous injection of 100 mg/kg body weight AG. Histochemical staining for NADPH diaphorase, which detects enzymatic activity of NOS, revealed positive reactivity in untreated EAE rats both in parenchymal blood vessel walls and in anterior horn cell neurons, while normal rats and rats with EAE treated with AG showed predominantly the neuronal positivity. Moreover, this NADPH staining pattern was further supported by the immunohistochemical findings that endothelial NOS (eNOS) expression was increased in blood vessels in the inflamed lesions of untreated EAE rats and that inducible NOS (iNOS) was detected in some infiltrating inflammatory cells, while treatment with AG could significantly reduce both iNOS and eNOS production. These results suggest that: (i) both iNOS and eNOS are upregulated in inflamed areas of the rat central nervous system in EAE; (ii) increased NO production plays a role in the development of clinical signs in EAE; and (iii) selective inhibitors of iNOS and/or eNOS may have therapeutic potential for the treatment of certain autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)123-133
Number of pages11
JournalJournal of Neuroimmunology
Volume64
Issue number2
DOIs
StatePublished - Feb 1996
Externally publishedYes

Fingerprint

Autoimmune Experimental Encephalomyelitis
Nitric Oxide Synthase
Anterior Horn Cells
Nitric Oxide Synthase Type III
Nitric Oxide Synthase Type II
Blood Vessels
Nitric Oxide
Protein Isoforms
Staining and Labeling
NADPH Dehydrogenase
Nitric Oxide Synthase Type I
Subcutaneous Injections
pimagedine
NADP
Endotoxins
Autoimmune Diseases
Therapeutics
Central Nervous System
Body Weight
Cytokines

Keywords

  • Aminoguanidine
  • Experimental allergic encephalomyelitis
  • Multiple sclerosis
  • NADPH diaphorase
  • Nitric oxide

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Zhao, W., Tilton, R., Corbett, J. A., McDaniel, M. L., Misko, T. P., Williamson, J. R., ... Hickey, W. F. (1996). Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. Journal of Neuroimmunology, 64(2), 123-133. https://doi.org/10.1016/0165-5728(95)00158-1

Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. / Zhao, Weiguo; Tilton, Ronald; Corbett, John A.; McDaniel, Michael L.; Misko, Thomas P.; Williamson, Joseph R.; Cross, Anne H.; Hickey, William F.

In: Journal of Neuroimmunology, Vol. 64, No. 2, 02.1996, p. 123-133.

Research output: Contribution to journalArticle

Zhao, W, Tilton, R, Corbett, JA, McDaniel, ML, Misko, TP, Williamson, JR, Cross, AH & Hickey, WF 1996, 'Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase', Journal of Neuroimmunology, vol. 64, no. 2, pp. 123-133. https://doi.org/10.1016/0165-5728(95)00158-1
Zhao, Weiguo ; Tilton, Ronald ; Corbett, John A. ; McDaniel, Michael L. ; Misko, Thomas P. ; Williamson, Joseph R. ; Cross, Anne H. ; Hickey, William F. / Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. In: Journal of Neuroimmunology. 1996 ; Vol. 64, No. 2. pp. 123-133.
@article{0ae02eaebc434695923a40cff5e53785,
title = "Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase",
abstract = "This study assessed the role of de novo nitric oxide (NO) production in the pathogenesis of experimental allergic encephalomyelitis (EAE) by using aminoguanidine (AG), an inhibitor of nitric oxide synthase (NOS), which preferentially inhibits the cytokine- and endotoxin-inducible isoform of NOS versus the constitutive isoforms consisting of endothelial and neuronal NOS. The maximum clinical severity of EAE and the duration of illness were significantly reduced or totally inhibited by twice daily subcutaneous injection of 100 mg/kg body weight AG. Histochemical staining for NADPH diaphorase, which detects enzymatic activity of NOS, revealed positive reactivity in untreated EAE rats both in parenchymal blood vessel walls and in anterior horn cell neurons, while normal rats and rats with EAE treated with AG showed predominantly the neuronal positivity. Moreover, this NADPH staining pattern was further supported by the immunohistochemical findings that endothelial NOS (eNOS) expression was increased in blood vessels in the inflamed lesions of untreated EAE rats and that inducible NOS (iNOS) was detected in some infiltrating inflammatory cells, while treatment with AG could significantly reduce both iNOS and eNOS production. These results suggest that: (i) both iNOS and eNOS are upregulated in inflamed areas of the rat central nervous system in EAE; (ii) increased NO production plays a role in the development of clinical signs in EAE; and (iii) selective inhibitors of iNOS and/or eNOS may have therapeutic potential for the treatment of certain autoimmune diseases.",
keywords = "Aminoguanidine, Experimental allergic encephalomyelitis, Multiple sclerosis, NADPH diaphorase, Nitric oxide",
author = "Weiguo Zhao and Ronald Tilton and Corbett, {John A.} and McDaniel, {Michael L.} and Misko, {Thomas P.} and Williamson, {Joseph R.} and Cross, {Anne H.} and Hickey, {William F.}",
year = "1996",
month = "2",
doi = "10.1016/0165-5728(95)00158-1",
language = "English (US)",
volume = "64",
pages = "123--133",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase

AU - Zhao, Weiguo

AU - Tilton, Ronald

AU - Corbett, John A.

AU - McDaniel, Michael L.

AU - Misko, Thomas P.

AU - Williamson, Joseph R.

AU - Cross, Anne H.

AU - Hickey, William F.

PY - 1996/2

Y1 - 1996/2

N2 - This study assessed the role of de novo nitric oxide (NO) production in the pathogenesis of experimental allergic encephalomyelitis (EAE) by using aminoguanidine (AG), an inhibitor of nitric oxide synthase (NOS), which preferentially inhibits the cytokine- and endotoxin-inducible isoform of NOS versus the constitutive isoforms consisting of endothelial and neuronal NOS. The maximum clinical severity of EAE and the duration of illness were significantly reduced or totally inhibited by twice daily subcutaneous injection of 100 mg/kg body weight AG. Histochemical staining for NADPH diaphorase, which detects enzymatic activity of NOS, revealed positive reactivity in untreated EAE rats both in parenchymal blood vessel walls and in anterior horn cell neurons, while normal rats and rats with EAE treated with AG showed predominantly the neuronal positivity. Moreover, this NADPH staining pattern was further supported by the immunohistochemical findings that endothelial NOS (eNOS) expression was increased in blood vessels in the inflamed lesions of untreated EAE rats and that inducible NOS (iNOS) was detected in some infiltrating inflammatory cells, while treatment with AG could significantly reduce both iNOS and eNOS production. These results suggest that: (i) both iNOS and eNOS are upregulated in inflamed areas of the rat central nervous system in EAE; (ii) increased NO production plays a role in the development of clinical signs in EAE; and (iii) selective inhibitors of iNOS and/or eNOS may have therapeutic potential for the treatment of certain autoimmune diseases.

AB - This study assessed the role of de novo nitric oxide (NO) production in the pathogenesis of experimental allergic encephalomyelitis (EAE) by using aminoguanidine (AG), an inhibitor of nitric oxide synthase (NOS), which preferentially inhibits the cytokine- and endotoxin-inducible isoform of NOS versus the constitutive isoforms consisting of endothelial and neuronal NOS. The maximum clinical severity of EAE and the duration of illness were significantly reduced or totally inhibited by twice daily subcutaneous injection of 100 mg/kg body weight AG. Histochemical staining for NADPH diaphorase, which detects enzymatic activity of NOS, revealed positive reactivity in untreated EAE rats both in parenchymal blood vessel walls and in anterior horn cell neurons, while normal rats and rats with EAE treated with AG showed predominantly the neuronal positivity. Moreover, this NADPH staining pattern was further supported by the immunohistochemical findings that endothelial NOS (eNOS) expression was increased in blood vessels in the inflamed lesions of untreated EAE rats and that inducible NOS (iNOS) was detected in some infiltrating inflammatory cells, while treatment with AG could significantly reduce both iNOS and eNOS production. These results suggest that: (i) both iNOS and eNOS are upregulated in inflamed areas of the rat central nervous system in EAE; (ii) increased NO production plays a role in the development of clinical signs in EAE; and (iii) selective inhibitors of iNOS and/or eNOS may have therapeutic potential for the treatment of certain autoimmune diseases.

KW - Aminoguanidine

KW - Experimental allergic encephalomyelitis

KW - Multiple sclerosis

KW - NADPH diaphorase

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0029871609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029871609&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(95)00158-1

DO - 10.1016/0165-5728(95)00158-1

M3 - Article

C2 - 8632054

AN - SCOPUS:0029871609

VL - 64

SP - 123

EP - 133

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -